Ucb SA 2012 AR2
The report highlights UCB's transformation into a patient-centric biopharmaceutical company in 2012, achieving revenues of ‒3.46 billion and a net profit of ‒252 million. Key growth drivers included the core medicines Cimzia, Vimpat, and Neupro, which reached combined sales of ‒934 million. The company invested 26% of its revenue in research and development to advance its promising pipeline, including three potential medicines in Phase 3 development. Additionally, UCB launched its new Corporate Societal Responsibility strategy, focusing on patient-centricity in developing countries and planet-centricity to reduce its ecological footprint.
Company: Ucb SA
Sector: Manufacturing
Country: Belgium
Year: 2012
Type: AR2
Pages: 150
Back to company
Ucb SA
Annual Report
The report highlights UCB's transformation into a patient-centric biopharmaceutical company in 2012, achieving revenues of ‒3.46 billion and a net profit of ‒252 million. Key growth drivers included the core medicines Cimzia, Vimpat, and Neupro, which reached combined sales of ‒934 million. The company invested 26% of its revenue in research and development to advance its promising pipeline, including three potential medicines in Phase 3 development. Additionally, UCB launched its new Corporate Societal Responsibility strategy, focusing on patient-centricity in developing countries and planet-centricity to reduce its ecological footprint.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2012
Reporting Period
Jan 1, 2012 - Dec 31, 2012
Fiscal Year
2012
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Employees